SCHEMBL10102268

SCHEMBL10102268

COc1ccc(C2(c3ccc(N(C)C)cc3)C=Cc3c(C)cc4c(C)cc(N(C)C)cc4c3O2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.36
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPT P10636 2/20 0.33
APP P05067 2/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32
NPC1 O15118 1/20 0.31
TP53 P04637 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102406 0.94 SLC2A1 (0.36) SLC2A1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10106936 0.93 SLC2A1 (0.36) SLC2A1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10102270 0.88 CALM1 (0.32) SLC2A1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL6131956 0.88 SLC2A1 (0.35) SLC2A1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7528138 0.85 MEN1 (0.33) SLC2A1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7525851 0.82 TDP1 (0.32) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL7528995 0.79 ALDH1A1 (0.37) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL6995620 0.75 GPR84 (0.38) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL7528300 0.74 PKM (0.37) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL7530319 0.74 LMNA (0.35) KDM4EALDH1A1HPGDHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 SLC2A1 4691/4885KDM4E 1435/4885ALDH1A1 1382/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 SLC2A1 3366/4885KDM4E 2629/4885ALDH1A1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.